First Quarter Fiscal 2027 Results

August 6, 2026

HAEMONETICS®

Q1 Fiscal 2027 Conference Call Detail

Conference call will take place at **8:00 a.m. ET** on **August 6, 2026,** and can be accessed via live webcast: Link or teleconference: Link.

The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 a.m. ET) are available online at www.haemonetics.com.

CONFERENCE CALL SPEAKERS

Chris Simon
President & CEO

James D'Arecca
EVP, Chief Financial Officer

Olga Guyette
VP, Investor Relations & Treasury

HAEMONETICS®

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation ("Haemonetics" or the "Company"), including plans or objectives related to the Company's strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company's market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company's share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the U.S. Securities Exchange Commission (the "SEC") under the headings "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" and in the Company's other periodic filings with the SEC. The Company does not undertake to update these forward-looking statements.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. Except with respect to organic revenue growth guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts.

When used in this presentation, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition, integration and divestiture related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment.

Use of Document

This presentation contains certain highlights with respect to our first quarter of fiscal 2027 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our earnings release for the first quarter ended June 27, 2026 located in the investor relations section of our website at www.haemonetics.com and our Quarterly Report on Form 10-Q for the quarter ended June 27, 2026 filed with the SEC.

Q1 Fiscal 2027 Highlights

Broad-based Profitable Growth

All three growth platforms contributed to **6%** organic revenue and **4%** adjusted earnings growth

Raised FY27 guidance following strong Q1 performance

Strong cash generation with Q1 free cash flow increasing **~15X** YoY, and TTM[1] free cash flow conversion of **106%**

Executing Our Strategy

Accelerating Persona® PLUS adoption strengthens the NexSys PCS® platform

Interventional Technologies returns to growth; VASCADE MVP® XL system label helps accelerate momentum

Blood Management Technologies continues to demonstrate durable growth across the franchise

Building a Higher-quality Business

Multiple growth platforms are driving a more durable growth profile

Continued strong cash generation enabled repayment of $100 million on the revolving credit facility[2]

Differentiated innovation continues to expand long-term growth opportunities

1) Trailing twelve months. 2) Includes $50 million repayment in Q1 and an additional $50 million repayment in Q2.

Q1 Fiscal 2027 Revenue by Business Unit

REVENUE

(in millions)



(in millions)	Q1 2027	Q1 2026	REPORTED GROWTH	ORGANIC GROWTH[1]
Plasma	$155.5	$145.1	7.2%	8.2%
Other[2]	$35.8	$36.7	(2.4%)	(2.8%)
Apheresis	**$191.3**	**$181.7**	**5.3%**	**6.0%**
Interventional Technologies[3]	$59.9	$58.5	2.5%	2.8%
Blood Management Technologies[4]	$88.1	$81.2	8.6%	8.1%
MedSurg	**$148.1**	**$139.7**	**6.0%**	**5.9%**
Total Net Revenues	**$339.4**	**$321.4**	**5.6%**	**5.9%**

1) Includes the impact of the exit of certain liquid solution products and nominal historical pre-acquisition revenue of Vivasure. 2) Other includes blood collection and processing devices and disposables. 3) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.

HAEMONETICS®

Q1 Fiscal 2027 Financial Review

GAAP RESULTS

	Q1 2027	Q1 2026	Y/Y
Gross Margin %	59.8%	59.8%	- bps
Operating Margin %	16.9%	16.8%	+10bps
Net Income Margin %	9.7%	10.6%	-90bps
Income Tax Rate	30.6%	24.7%	+590bps
Earnings Per Share	$0.72	$0.70	3%

NON-GAAP RESULTS

	Q1 2027	Q1 2026	Y/Y
Adjusted Gross Margin %	60.4%	60.8%	-40bps
Adjusted Operating Margin %	23.4%	24.1%	-70bps
Adjusted Net Income Margin %	15.4%	16.6%	-120bps
Adjusted Income Tax Rate	25.7%	24.9%	+80bps
Adjusted Earnings Per Share	$1.14	$1.10	4%

HAEMONETICS®

Q1 Fiscal 2027 Segment Performance

APHERESIS

	Q1 2027	Q1 2026	Y/Y
Revenue	$191.3M	$181.7M	5.3% reported / 6.0% organic
Adjusted Operating Margin %[1]	29.6%	32.6%	-300bps

MEDSURG

	Q1 2027	Q1 2026	Y/Y
Revenue	$148.1M	$139.7M	6.0% reported / 5.9% organic
Adjusted Operating Margin %[1]	15.3%	13.2%	+210bps

1) Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company's enterprise resource planning system, unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Total corporate and unallocated expenses were $21.8M in Q1 FY'27 and $23.7M in Q1 FY'26. Please refer to the reconciliation table in Appendix D of this presentation for more information.

HAEMONETICS®

Balance Sheet and Cash Flow Metrics

CASH FROM OPERATIONS

(dollars in millions)



75%	5%	106%	62%

Free cash flow to adjusted net income ratio

(in millions)	6/27/26	3/28/26
Cash & cash equivalents	$223	$245
Working capital	$548	$552
Total debt	$1,174	$1,225
Net debt[1]	$951	$980
Available credit[2]	$749	$749
Gross leverage ratio[3]	2.82	2.97
Net leverage ratio[3]	2.69	2.73

1) Net debt is calculated as total debt minus cash & cash equivalents. 2) Available borrowing capacity under the existing revolving credit facility minus any eligible letters of credit. 3) Gross and net leverage ratios per the terms set forth in the Company's existing credit agreement. 4) Includes capital expenditures, non-cash inventory transfers of Haemonetics equipment and proceeds from the sale of property, plant and equipment.

HAEMONETICS®

Full-Year Fiscal 2027 Guidance

	GUIDANCE AS OF MAY 7, 2026[3]	GUIDANCE AS OF AUGUST 6, 2026
Reported Revenue	**4 – 7%**	**5 – 8%**
53rd Week Impact	(~2%)	(~2%)
Currency Impact	0 – 1%	0 – 1%
Organic Revenue[1]	**3 – 6%**	**4 – 7%**
Apheresis	LSD Growth	LSD to MSD Growth
MedSurg	MSD Growth	MSD Growth
Adjusted Operating Margin	**50 – 100 bps expansion YoY**	**50 – 100 bps expansion YoY**
Adjusted EPS	**Comparable to reported revenue growth**	**Comparable to reported revenue growth**
Free cash flow conversion[2]	**~80%**	**~80%**

1) Organic revenue growth guidance excludes the impact of currency fluctuation and the exit of certain liquid solution products. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance. 2) Free cash flow conversion is calculated as free cash flow divided by adjusted net income. 3) Recast as of June 5, 2026 announcement of updates to financial reporting segments solely to align previously issued guidance with the new reportable segment structure.

Appendices

HAEMONETICS®

Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates

($ millions)	Q1 2027	Q1 2026	Reported growth	Currency impact	Acquisitions & Divestitures[1]	Organic growth[2]
Plasma	$155.5	$145.1	7.2%	0.1%	(1.1%)	8.2%
Other[3]	$35.8	$36.7	(2.4%)	0.4%	–	(2.8%)
Apheresis	$191.3	$181.7	5.3%	0.2%	(0.9%)	6.0%
Interventional Technologies[4]	$59.9	$58.5	2.5%	(0.3%)	–	2.8%
Blood Management Technologies[5]	$88.1	$81.2	8.6%	0.5%	–	8.1%
MedSurg	$148.1	$139.7	6.0%	0.1%	–	5.9%
Total Net Revenues	$339.4	$321.4	5.6%	0.2%	(0.5%)	5.9%

1) Includes the impact of the exit of certain liquid solution products. 2) Includes nominal historical pre-acquisition revenue of Vivasure. 3) Other includes blood collection and processing devices and disposables. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage, and Transfusion Management product lines of the MedSurg business unit.

HAEMONETICS®

Appendix B: Reconciliation of GAAP to Non-GAAP Q1 Fiscal 2027 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income	Interest and other income (expense)	Provision (benefit) for income taxes	Net income	Earnings per diluted share
Reported	$202.8	$145.3	$57.5	($9.9)	$14.6	$33.0	$0.72
Amortization of acquired intangible assets	–	($10.2)	$10.2	–	$2.3	$7.9	$0.16
Integration and transaction costs	$1.3	($1.4)	$2.7	–	($0.4)	$3.1	$0.07
Restructuring costs	$0.8	($1.5)	$2.3	–	$0.5	$1.8	$0.04
Restructuring related costs	–	$0.1	–	–	–	–	–
Digital transformation costs	–	($6.2)	$6.2	–	$1.6	$4.6	$0.10
Litigation-related charges	–	($0.5)	$0.5	–	–	$0.5	$0.01
Equity method losses	–	–	–	$1.0	$0.3	$0.7	$0.02
Discrete tax items	–	–	–	–	($0.7)	$0.7	$0.02
Adjusted	$204.9	$125.6	$79.3	($8.9)	$18.1	$52.3	$1.14
Adjusted, as a percentage of net revenues	60.4%	37.0%	23.4%			15.4%	

HAEMONETICS®

Appendix B: Reconciliation of GAAP to Non-GAAP Q1 Fiscal 2026 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other income (expense)	Provision for income taxes	Net income (loss)	Earnings per diluted share
Reported	$192.2	$138.4	$53.9	($8.7)	$11.1	$34.0	$0.70
Amortization of acquired intangible assets	–	($11.4)	$11.4	–	$2.9	$8.5	$0.18
Amortization of fair value inventory step up	$2.4	–	$2.4	–	$0.6	$1.8	$0.04
Integration and transaction costs	$1.0	($1.7)	$2.7	$2.0	$1.2	$3.5	$0.07
Restructuring costs	($0.4)	($1.7)	$1.3	–	$0.3	$1.0	$0.02
Restructuring related costs	–	($0.1)	$0.1	–	–	–	–
Digital transformation costs	–	($5.4)	$5.4	–	$1.3	$4.0	$0.08
Litigation-related charges	–	($0.6)	$0.6	–	$0.1	$0.4	$0.01
Remeasurement of contingent consideration	–	$0.1	($0.1)	–	–	($0.1)	–
Adjusted	$195.3	$117.8	$77.6	($6.7)	$17.6	$53.2	$1.10
Adjusted, as a percentage of net revenues	60.8%	36.6%	24.1%			16.6%	

HAEMONETICS®

Appendix C: Reconciliation of Cash Flows

($ millions)	Q1 2027	Q1 2026
Free Cash Flow Reconciliation		
Cash provided by operating activities	$52.3	$17.4
Capital expenditures	($7.9)	($3.8)
Additions to Haemonetics equipment	($5.6)	($11.5)
Proceeds from sale of property, plant and equipment	$0.2	$0.3
Free cash flow	$39.1	$2.5

Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2)

($ millions)	Q1 2027	Q1 2026
Net revenues:		
Apheresis	$191.3	$181.7
MedSurg	$148.1	$139.7
Total net revenues	**$339.4**	**$321.4**
Significant segment expenses and operating performance:		
Apheresis		
Cost of goods sold	$84.1	$75.9
Selling, general and administrative	$44.3	$39.9
Research and development	$6.4	$6.8
Apheresis operating income	$56.5	$59.2
MedSurg		
Cost of goods sold	$50.4	$50.2
Selling, general and administrative	$65.2	$62.3
Research and development	$9.8	$8.7
MedSurg operating income	$22.7	$18.4

HAEMONETICS®

Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2)

($ millions)	Q1 2027	Q1 2026
Corporate and unallocated expenses		
Amortization of acquired assets	($10.2)	($13.8)
Integration and transaction costs	($2.7)	($2.7)
Restructuring and restructuring related costs	($2.3)	($1.3)
Digital transformation costs	($6.2)	($5.4)
Other[1]	($0.5)	($0.5)
Operating income	$57.5	$53.9
Interest and other expense, net	($9.9)	($8.7)
Income before provision for income taxes	**$47.6**	**$45.2**

1) Comprised of litigation-related charges and remeasurement of contingent consideration for the three months ended June 27, 2026 and June 28, 2025.

Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results[1]

($ millions)	TTM Q1 FY27 Net income (loss)	TTM Q1 FY26 Net income (loss)
Reported	$96.3	$163.3
Amortization of acquired intangible assets	$32.6	$35.4
Amortization of fair value inventory step up	$2.6	$9.2
Acquisition, Integration, transaction and divestiture costs	$12.8	$7.7
Restructuring costs	$3.1	$7.9
Restructuring related costs	–	$3.7
Digital transformation costs	$16.9	$14.7
Write downs of certain in-process intangible assets and PCS2 related charges	$0.7	$3.0
MDR and IVDR costs	–	$2.8
Litigation-related charges	–	$2.0
Impairment of intangible assets	$65.3	$1.8
Remeasurement of contingent consideration	($1.5)	($20.8)
Provision for pre-acquisition inventory	$5.5	–
Equity method losses	($0.7)	–
Discrete tax items	($1.2)	$1.7
Adjusted	$233.8	$232.4
Adjusted, as a percentage of net revenues	17.3%	17.3%

($ millions)	TTM Q1 FY27	TTM Q1 FY26
Free Cash Flow Reconciliation		
Cash provided by operating activities	$328.2	$226.5
Capital expenditures	($36.9)	($37.4)
Additions to Haemonetics' equipment	($46.0)	($28.4)
Proceeds from sale of property, plant and equipment	$1.3	$3.2
Free cash flow	$246.5	$164.0

1) Reflects non-GAAP adjustments for each of the four subsequent quarters ending June 27, 2026 and June 28, 2025, respectively.